Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Sarepta Therapeutics to “Hold” from “Buy,” adding to mixed analyst sentiment. MarketBeat reports nine Buy, five Hold and six Sell ratings, with an average rating of “Hold” and a consensus price target of $25.06.
• Sarepta shares opened at $16.78, near the lower end of their 52-week range of $14.68 to $25.32. The company’s latest reported quarter beat earnings and revenue estimates, although revenue declined 1.9% year over year and profitability remained pressured.
• Recent updates point to both opportunities and risks: management is advancing its siRNA pipeline, but weaker-than-expected Elevidys sales, a narrowed 2026 revenue outlook and competitive pressures could weigh on future growth.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Several other research analysts have also recently issued reports on SRPT. Zacks Research cut shares of Sarepta Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 7th. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a research note on Thursday, July 9th. Weiss Ratings lowered shares of Sarepta Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research note on Wednesday. HC Wainwright restated a "buy" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Finally, Wolfe Research upgraded Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 price target for the company in a report on Thursday, July 9th. Nine equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and six have assigned a Sell rating to the company's stock. According to MarketBeat.com, Sarepta Therapeutics has an average rating of "Hold" and a consensus price target of $25.06.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $16.78 on Friday. The stock has a market cap of $1.77 billion, a P/E ratio of -5.79, a P/E/G ratio of 0.18 and a beta of 0.23. The firm's 50-day simple moving average is $16.92 and its 200 day simple moving average is $18.51. Sarepta Therapeutics has a fifty-two week low of $14.68 and a fifty-two week high of $25.32. The company has a quick ratio of 2.62, a current ratio of 4.42 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $2.18. The firm had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.15 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. Sarepta Therapeutics's revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($3.42) EPS. Equities analysts expect that Sarepta Therapeutics will post 3.89 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $25,000. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth approximately $25,000. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 1,000 shares during the period. Meeder Asset Management Inc. bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at about $27,000. Finally, Allworth Financial LP raised its stake in Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company's stock valued at $35,000 after buying an additional 1,721 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Options activity turned notably bullish: traders purchased 4,625 call options on Friday, about 47% above the typical daily volume of 3,153 contracts. This suggests increased speculative interest in an upside move, although options activity does not guarantee a sustained rally.
• Positive Sentiment: Sarepta exceeded Wall Street expectations in the second quarter of 2026, reporting earnings of $0.64 per share versus the $0.58 consensus estimate and delivering a revenue beat of approximately 12.85%. The company also reported $13 million in GAAP operating income, highlighting improved profitability. Sarepta Q2 earnings and revenue results
• Positive Sentiment: Management emphasized progress in its siRNA pipeline and a strategic shift under its recently appointed chief executive officer. Pipeline advances could help diversify Sarepta beyond its current commercial products and strengthen the longer-term investment case. Sarepta Q2 earnings call highlights
• Neutral Sentiment: The company’s financial performance improved, but reported earnings were below the $2.02 per-share result from the same quarter last year. Investors may therefore focus on whether the profitability gains are sustainable.
• Negative Sentiment: Elevidys sales were weaker than expected, and Sarepta narrowed its 2026 product-revenue outlook while tightening expense guidance. The lower outlook could offset the positive impact of the quarterly earnings and revenue beats. Sarepta Q2 earnings and 2026 outlook
• Negative Sentiment: RBC highlighted competitive pressures despite Sarepta’s pipeline updates. That raises concerns about Elevidys’ future sales trajectory and the company’s ability to maintain growth in a more competitive rare-disease market. RBC analysis of Sarepta competitive pressures

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source